ArticleBMC gastroenterology2026
Hepatocellular carcinoma risk, net survival and relative survival ratio in a high-income country of the Eastern Mediterranean Region: 2008-2020.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis cross-sectional cohort study aimed to estimate the incidence of hepatocellular carcinoma (HCC) and evaluate population-based net survival (NS) and relative survival ratios (RSR) among HCC patients in Kuwait.
methodsData from confirmed HCC cases diagnosed between 2008 and 2020, along with population data, were used to calculate age-standardized incidence rates (ASIR) per 10⁵ person-years using the world standard population as the reference. The Pohar-Perme estimator and annual all-cause mortality life tables were used to compute 1-, 3-, and 5-year NS, while the life table approach was applied to estimate RSR.
resultsA total of 439 HCC patients were included. The overall ASIR (per 10⁵ person-years) was 7.66 (95% CI: 6.97-8.40), higher in males (9.14; 95% CI: 8.22-10.13) than females (3.71; 95% CI: 3.69-5.63). Cumulative NS estimates (%) decreased over time and were consistently lower among males (1-year: 47.1; 95% CI: 41.1-54.1; 3-year: 23.5; 95% CI: 17.2-32.0; 5-year: 10.8; 95% CI: 5.4-21.7) than females (1-year: 54.6; 95% CI: 43.8-69.6; 3-year: 40.9; 95% CI: 26.6-62.8; 5-year: 26.3; 95% CI: 10.4-66.7). Similarly, RSRs were lower among males than females at 1-year (0.45 vs. 0.67), 3-year (0.22 vs. 0.56), and 5-year (0.15 vs. 0.25).
conclusionMarked sex differences were observed in HCC incidence, NS, and RSR, with female patients demonstrating more favorable survival outcomes at 1-, 3-, and 5-year. Further studies are needed to clarify the biological, clinical, and health-system factors contributing to these disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.